Zobrazeno 1 - 10
of 595
pro vyhledávání: '"Ursula A Matulonis"'
Autor:
Marcin Straczkiewicz, Nancy L Keating, Embree Thompson, Ursula A Matulonis, Susana M Campos, Alexi A Wright, Jukka-Pekka Onnela
Publikováno v:
JMIR Cancer, Vol 9, p e47646 (2023)
BackgroundStep counts are increasingly used in public health and clinical research to assess well-being, lifestyle, and health status. However, estimating step counts using commercial activity trackers has several limitations, including a lack of rep
Externí odkaz:
https://doaj.org/article/c7ebc1bc16b6417d83505fee438ea2bd
Autor:
Mei Zeng, Nicholas P Kwiatkowski, Tinghu Zhang, Behnam Nabet, Mousheng Xu, Yanke Liang, Chunshan Quan, Jinhua Wang, Mingfeng Hao, Sangeetha Palakurthi, Shan Zhou, Qing Zeng, Paul T Kirschmeier, Khyati Meghani, Alan L Leggett, Jun Qi, Geoffrey I Shapiro, Joyce F Liu, Ursula A Matulonis, Charles Y Lin, Panagiotis A Konstantinopoulos, Nathanael S Gray
Publikováno v:
eLife, Vol 7 (2018)
High-grade serous ovarian cancer is characterized by extensive copy number alterations, among which the amplification of MYC oncogene occurs in nearly half of tumors. We demonstrate that ovarian cancer cells highly depend on MYC for maintaining their
Externí odkaz:
https://doaj.org/article/28fdc67b84ee4b348cb7df68b272d1b0
Autor:
Ayaz Najafov, Ioannis K Zervantonakis, Adnan K Mookhtiar, Patricia Greninger, Ryan J March, Regina K Egan, Hoang Son Luu, Daniel G Stover, Ursula A Matulonis, Cyril H Benes, Junying Yuan
Publikováno v:
PLoS Biology, Vol 16, Iss 8, p e2005756 (2018)
Necroptosis is a lytic programmed cell death mediated by the RIPK1-RIPK3-MLKL pathway. The loss of Receptor-interacting serine/threonine-protein kinase 3 (RIPK3) expression and necroptotic potential have been previously reported in several cancer cel
Externí odkaz:
https://doaj.org/article/2e140e19f51e4e62a0336885df594129
Publikováno v:
Frontiers in Oncology, Vol 3 (2013)
Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy and the fifth most common cause of female cancer death in the United States. Although important advances in surgical and chemotherapeutic strategies over the last three decades
Externí odkaz:
https://doaj.org/article/a92572acfbb74541b9cea4518f4778c7
Autor:
Nicolai Juul Birkbak, Bose Kochupurakkal, Jose M G Izarzugaza, Aron C Eklund, Yang Li, Joyce Liu, Zoltan Szallasi, Ursula A Matulonis, Andrea L Richardson, J Dirk Iglehart, Zhigang C Wang
Publikováno v:
PLoS ONE, Vol 8, Iss 11, p e80023 (2013)
BackgroundIncreased number of single nucleotide substitutions is seen in breast and ovarian cancer genomes carrying disease-associated mutations in BRCA1 or BRCA2. The significance of these genome-wide mutations is unknown. We hypothesize genome-wide
Externí odkaz:
https://doaj.org/article/af39aee1554b495da94db92c355a9275
Autor:
Stefan Bentink, Benjamin Haibe-Kains, Thomas Risch, Jian-Bing Fan, Michelle S Hirsch, Kristina Holton, Renee Rubio, Craig April, Jing Chen, Eliza Wickham-Garcia, Joyce Liu, Aedin Culhane, Ronny Drapkin, John Quackenbush, Ursula A Matulonis
Publikováno v:
PLoS ONE, Vol 7, Iss 2, p e30269 (2012)
Ovarian cancer is the fifth leading cause of cancer death for women in the U.S. and the seventh most fatal worldwide. Although ovarian cancer is notable for its initial sensitivity to platinum-based therapies, the vast majority of patients eventually
Externí odkaz:
https://doaj.org/article/882777890708423181fff7a4cf12a1ab
Autor:
Ursula A Matulonis, Michelle Hirsch, Emanuele Palescandolo, Eejung Kim, Joyce Liu, Paul van Hummelen, Laura MacConaill, Ronny Drapkin, William C Hahn
Publikováno v:
PLoS ONE, Vol 6, Iss 9, p e24433 (2011)
BACKGROUND:Epithelial ovarian cancer is the most lethal of all gynecologic malignancies, and high grade serous ovarian cancer (HGSC) is the most common subtype of ovarian cancer. The objective of this study was to determine the frequency and types of
Externí odkaz:
https://doaj.org/article/8e51a7e43ef44f39b5c050d57843a018
Autor:
Panagiotis A. Konstantinopoulos, Niya Xiong, Carolyn Krasner, Joyce F. Liu, Hannah Sawyer, Madeline Polak, Hope Needham, Megan Geddes, Lani Koppermann, Meghan Shea, Cesar Castro, Su-Chun Cheng, Ursula A. Matulonis, Elizabeth K. Lee
Publikováno v:
Gynecologic Oncology Reports, Vol 52, Iss , Pp 101348- (2024)
Several lines of preclinical evidence indicate that combining PI3K and CDK4/6 inhibitors may further enhance the efficacy of hormonal therapy by overcoming de novo and acquired resistance to PI3K and CDK4/6 blockade. We evaluated the combination of a
Externí odkaz:
https://doaj.org/article/a58a03d3330d4b9d9bd8d84d99a74acc
Autor:
Richard T Penson, Allison J Ambrosio, Christin A Whalen, Carolyn N Krasner, Panagiotis A Konstantinopoulos, Charles Bradley, Ursula A Matulonis, Michael J Birrer
Publikováno v:
The Oncologist. 28:252-257
Background Iniparib (BSI-201), a novel anticancer agent thought to have poly(ADP-ribose) polymerase (PARP) inhibitory activity and synergy with both gemcitabine and carboplatin (GC) was evaluated in 2 cohorts with GC. Methods Parallel multicenter, si
Autor:
Joyce F. Liu, Mark F. Brady, Ursula A. Matulonis, Austin Miller, Elise C. Kohn, Elizabeth M. Swisher, David Cella, William P. Tew, Noelle G. Cloven, Carolyn Y. Muller, David P. Bender, Richard G. Moore, David P. Michelin, Steven E. Waggoner, Melissa A. Geller, Keiichi Fujiwara, Stacy D. D'Andre, Michael Carney, Angeles Alvarez Secord, Katherine M. Moxley, Michael A. Bookman
Publikováno v:
J Clin Oncol
PURPOSE Platinum-based chemotherapy is the standard of care for platinum-sensitive ovarian cancer, but complications from repeated platinum therapy occur. We assessed the activity of two all-oral nonplatinum alternatives, olaparib or olaparib/cediran